![Bryan Irving](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bryan Irving
Corporate Officer/Principal bij
3T Biosciences, Inc.
Profiel
Bryan A Irving is currently the Chief Scientific Officer at 3T Biosciences, Inc. He previously worked as a Senior Advisor at Frazier Management LLC, Chief Scientific Officer & Executive VP at Five Prime Therapeutics, Inc., Vice President & Cancer Immunology at CytomX Therapeutics Holdings LLC, and Chief Scientific Officer at Amunix Pharmaceuticals, Inc. Dr. Irving received his undergraduate degree from the University of California, Berkeley and his doctorate from The University of California, San Francisco.
Actieve functies van Bryan Irving
| Bedrijven | Functie | Begin |
|---|---|---|
3T Biosciences, Inc.
 3T Biosciences, Inc. BiotechnologyHealth Technology Operates as an immunotherapy company that develops next-generation and transformative therapies for the treatment of solid tumors and immune-mediated diseases | Corporate Officer/Principal | 01-10-2023 |
Eerdere bekende functies van Bryan Irving
| Bedrijven | Functie | Einde |
|---|---|---|
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer | Corporate Officer/Principal | 01-07-2022 |
| FIVE PRIME THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 30-05-2019 |
CytomX Therapeutics Holdings LLC
 CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology Engaged in the development of new generation targeted antibody therapeutics | Private Equity Investor | 01-08-2017 |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements. | Consultant / Adviseur | - |
Opleiding van Bryan Irving
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
31
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm targets companies operating in the fields of medical products & distribution, pharmaceuticals and healthcare service sectors. It provides financing for buyout and growth stage capital requirements. | Finance |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology Engaged in the development of new generation targeted antibody therapeutics | Health Technology |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer | Health Technology |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology Operates as an immunotherapy company that develops next-generation and transformative therapies for the treatment of solid tumors and immune-mediated diseases | Health Technology |
